WW INTERNATIONAL, INC.

WW International, Inc. reported a net loss of $37.9 million for the six months ended June 30, 2026, with basic net loss per share at $3.79. Total revenue for the period was $330.6 million. The company continues to face significant market disruption and competitive pressures, including the rapid adoption of GLP-1 medications, which have negatively impacted its Behavioral business, despite growth in its Clinical segment. The financial statements reflect fresh start accounting following the company's emergence from Chapter 11 bankruptcy on June 24, 2025, making prior periods non-comparable.

WW International, Inc. announced its Q2 2026 financial results, reporting revenue of $162.3 million and net income of $14.1 million. The company saw significant growth in its Clinical Subscribers, up 55.7% year-over-year to 197 thousand, and Core+ Subscribers increased 13.9% to 541 thousand. WW International also reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance and reduced its term loan principal by $41.4 million.

WW International, Inc. announced it will release its second quarter 2026 financial results, for the period ended June 30, 2026, after market close on Wednesday, August 5, 2026. Following the release, the company will host a conference call at 5:00 p.m. ET on the same day to discuss the results. A webcast of the call will be accessible on the company's corporate website, with a replay available for at least 90 days.

WW International (Weight Watchers) and Sam's Club announced a new collaboration to provide a more connected and affordable wellness experience for Sam's Club members. Sam's Club Plus members are eligible for a complimentary three-month Weight Watchers Core membership, valued at $54, with an option to continue for $10 per month. All Sam's Club members can access special pricing, saving up to 50% on Weight Watchers Core+ and Med+ programs. This partnership integrates nutrition counseling, healthy food choices, and trusted pharmacy care to support members' wellness goals.

WW International, Inc. announced a new summer collaboration with FlavCity, a health and wellness brand. This partnership introduces the limited-edition Weight Watchers x FlavCity® Whipped Lemonade protein smoothie powder, featuring 25 grams of protein and 10 grams of collagen. Concurrently, the company launched the 'Summer Strength Club,' a 10-week member experience designed to help participants build strength and maintain nutrition goals through expert coaching, workouts, recipes, and community support.

WW International, Inc. announced that its Weight Watchers Med+ program will support Medicare members seeking access to GLP-1 medications through the new Medicare GLP-1 Bridge Program. This program, running from July 1, 2026, to December 31, 2027, allows eligible beneficiaries to purchase GLP-1 medications for $50 per month. Weight Watchers Med+ will assist members with prescriptions, care management, insurance navigation, and provide comprehensive behavioral support, including nutrition guidance and strength-building exercises.

WW International, Inc. announced a partnership with the American Heart Association to support the Healthy Living BEYOND Weight™ Study. This collaboration aims to deepen the understanding of real-world weight health and improve care for individuals living with obesity or who are overweight. WW is connecting its members to this research opportunity, highlighting its comprehensive care model that integrates medical support, nutrition, and behavioral guidance, particularly for those using GLP-1 medications. Internal analyses showed that WW Med+ members on GLP-1s who engaged in behavioral support lost significantly more weight.

WW International, Inc. and CheqUp announced a significant expansion of their partnership in the UK, integrating clinical and behavioral weight management support. This allows UK Weight Watchers members to access CheqUp's medical weight loss program, while CheqUp members continue to utilize the Weight Watchers app and GLP-1 Companion Programme. The collaboration aims to provide a more holistic and connected weight health experience, aligning with the growing recognition of GLP-1 medication benefits and the need for comprehensive support.

WW International, Inc. announced a Settlement Agreement with its former President and Chief Executive Officer, Tara Comonte, following her resignation effective March 31, 2026. The agreement, entered into on May 14, 2026, outlines a total settlement payment of $1,850,000 to Ms. Comonte, paid in two installments, along with $150,000 for her attorneys' fees. The agreement also includes customary mutual releases of claims, a cooperation covenant, mutual non-disparagement, and confidentiality provisions.

WW International reported a net loss of $52.0 million for Q1 2026, an improvement from $72.6 million in Q1 2025, but revenue declined by 10.9% to $168.3 million. The financial statements reflect fresh start accounting following the company's emergence from Chapter 11 bankruptcy in June 2025, impacting comparability, especially for the significantly higher net loss per share of $(5.20). The company's Behavioral business saw a significant revenue decrease, while its Clinical business experienced growth, but overall cash flow from operations turned negative. Both goodwill for the Behavioral reporting unit and the trade name intangible asset were identified as being at risk for impairment.